In this vein, a retrospective analysis of tumour samples (oesophageal/gastric carcinomas and glioblastoma) from patients with a poor clinical response to anti-PD-1 antibody therapy demonstrated high tumour PD-L2 expression. Here, PDCD1LG2 is linked to neoplasm.